Gilead's landmark CAR-T approval leaves Bristol Myers Squibb scrambling for second place
You’ve got to be quicker than that, Bristol Myers Squibb. Gilead’s Kite scored a landmark approval for Yescarta in large B-cell lymphoma (LBCL) on Friday, making it the first CAR-T available in the second-line lymphoma setting.
The news comes just a few months ahead of an expected decision for BMS’ CAR-T rival Breyanzi in the same indication. Gilead says the approval should roughly double Yescarta’s market size in the US — a milestone Kite CEO Christi Shaw said has been “years in the making.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.